Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BETAMETHASONE DIPROPIONATE

Form:

6 of 6 products shown

All products: general benefit

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
  • Fluocinonide (Lyderm): general benefit, Not a benefit
  • Halobetasol (Bryhali): general benefit
  • Mometasone furoate (Elocom): general benefit

6 more in the class list below

Diprosone · DIN 00323071 · 0.05% · Cr

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diprosone · DIN 00323071 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-06-29 · brand DIPROSONE · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2048 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2071 · Verify on the e-Formulary ↗ (DIN 00323071)

Source record
DIN 00323071: Diprosone Raw flags: sec3=Y Item: 840600042; group id 836; item number 2031; lccId None; manufacturer id OCI Source form: Cr; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.2174; ministry $0.2048 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00323071 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2071
Interchangeable products
Taro-Sone · DIN 01925350 · $0.2048
Shortage status: resolved shortage (ended 2018-04-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00323071
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Sone · DIN 01925350 · 0.05% · Cr

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Sone · DIN 01925350 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 1992-12-31 · brand TARO-SONE · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 % · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Sone: Formulary list price $0.2048/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2048 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12272 · Verify on the e-Formulary ↗ (DIN 01925350)

Source record
DIN 01925350: Taro-Sone Raw flags: sec3=Y Item: 840600042; group id 836; item number 2031; lccId None; manufacturer id TAR Source form: Cr; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.2048; ministry $0.2048 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01925350 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12272
Interchangeable products
Diprosone · DIN 00323071 · $0.2048
Shortage status: resolved shortage (ended 2021-01-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01925350
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diprosone · DIN 00417246 · 0.05% · Lot

General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health CanadaMarketed · checked 2026-09-02
StatusGeneral benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Write on scriptno code needed; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diprosone · DIN 00417246 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-09-15 · brand DIPROSONE · ATC D07AC01 BETAMETHASONE · form Lotion · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1980 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2870 · Verify on the e-Formulary ↗ (DIN 00417246)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00417246). DIN 00417246: Diprosone Raw flags: dinStatus=E, sec3=Y Item: 840600048; group id 836; item number 2032; lccId None; manufacturer id OCI Source form: Lot; strength: 0.05% Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $0.2100; ministry $0.1980 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00417246 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2870
Interchangeable products
Ratio-Topisone · DIN 00809187 · $0.1980
Shortage status: discontinued (2026-06-11, reported by ORGANON CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00417246
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ratio-Topisone · DIN 00809187 · 0.05% · Lot

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Topisone · DIN 00809187 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-09-20 · brand TEVA-TOPISONE · ATC D07AC01 BETAMETHASONE · form Lotion · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Ratio-Topisone: Formulary list price $0.1980/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1980 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10941 · Verify on the e-Formulary ↗ (DIN 00809187)

Source record
DIN 00809187: Ratio-Topisone Raw flags: sec3=Y Item: 840600048; group id 836; item number 2032; lccId None; manufacturer id RPH Source form: Lot; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.1980; ministry $0.1980 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00809187 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10941
Interchangeable products
Diprosone · DIN 00417246 · $0.1980
Shortage status: discontinued (2024-06-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00809187
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diprosone · DIN 00344923 · 0.05% · Oint

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diprosone · DIN 00344923 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-06-16 · brand DIPROSONE · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2152 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2272 · Verify on the e-Formulary ↗ (DIN 00344923)

Source record
DIN 00344923: Diprosone Raw flags: sec3=Y Item: 840600047; group id 836; item number 2033; lccId None; manufacturer id OCI Source form: Oint; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.2284; ministry $0.2152 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00344923 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2272
Interchangeable products
Ratio-Topisone · DIN 00805009 · $0.2152
Shortage status: resolved shortage (ended 2019-11-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00344923
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ratio-Topisone · DIN 00805009 · 0.05% · Oint

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Topisone · DIN 00805009 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-09-20 · brand TEVA-TOPISONE · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Ratio-Topisone: Formulary list price $0.2152/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2152 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13888 · Verify on the e-Formulary ↗ (DIN 00805009)

Source record
DIN 00805009: Ratio-Topisone Raw flags: sec3=Y Item: 840600047; group id 836; item number 2033; lccId None; manufacturer id RPH Source form: Oint; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.2152; ministry $0.2152 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00805009 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13888
Interchangeable products
Diprosone · DIN 00344923 · $0.2152
Shortage status: active shortage (reported 2026-06-24, estimated to end 2026-08-10, last updated 2026-06-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00805009
Shortage record checked 2026-09-13T08:10:21.292534+00:00

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
  • Fluocinonide (Lyderm): general benefit, Not a benefit
  • Halobetasol (Bryhali): general benefit
  • Mometasone furoate (Elocom): general benefit

6 more in the class list below

Diprolene · DIN 00629367 · 0.05% · Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diprolene · DIN 00629367 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2023-08-08 · brand DIPROLENE · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Diprolene: Formulary list price $0.5186/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5186 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6529 · Verify on the e-Formulary ↗ (DIN 00629367)

Source record
DIN 00629367: Diprolene Raw flags: sec3=Y Item: 840600094; group id 837; item number 2034; lccId None; manufacturer id OCI Source form: Oint; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.5186; ministry $0.5186 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00629367 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6529
Interchangeable products
Ratio-Topilene · DIN 00849669 · $0.5186
Shortage status: resolved shortage (ended 2026-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00629367
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ratio-Topilene · DIN 00849669 · 0.05% · Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Topilene · DIN 00849669 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-11-28 · brand TEVA-TOPILENE · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 % · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Ratio-Topilene: Formulary list price $0.5186/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5186 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10940 · Verify on the e-Formulary ↗ (DIN 00849669)

Source record
DIN 00849669: Ratio-Topilene Raw flags: sec3=Y Item: 840600094; group id 837; item number 2034; lccId None; manufacturer id RPH Source form: Oint; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.5186; ministry $0.5186 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00849669 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10940 Therapeutic Notes (formulary) No more than 50 grams per week of ultrapotent steroids for a maximum of 2 weeks is recommended.
Interchangeable products
Diprolene · DIN 00629367 · $0.5186
Shortage status: active shortage (reported 2024-08-28, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00849669
Shortage record checked 2026-09-13T08:10:21.292534+00:00

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

All products: general benefit

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
  • Fluocinonide (Lyderm): general benefit, Not a benefit
  • Halobetasol (Bryhali): general benefit
  • Mometasone furoate (Elocom): general benefit

6 more in the class list below

Ratio-Topilene · DIN 00849650 · 0.05% · Cr

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Topilene · DIN 00849650 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-11-28 · brand TEVA-TOPILENE · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 % · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Ratio-Topilene: Formulary list price $0.5186/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5186 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14445 · Verify on the e-Formulary ↗ (DIN 00849650)

Source record
DIN 00849650: Ratio-Topilene Raw flags: sec3=Y Item: 840600105; group id 838; item number 2035; lccId None; manufacturer id RPH Source form: Cr; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.5186; ministry $0.5186 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00849650 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14445 Therapeutic Notes (formulary) No more than 50 grams per week of ultrapotent steroids for a maximum of 2 weeks is recommended.
Interchangeable products
Diprolene Glycol · DIN 00688622 · $0.5186
Shortage status: resolved shortage (ended 2025-11-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00849650
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diprolene Glycol · DIN 00688622 · 0.05% · Cr

General benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.Discontinued 2019-06-28 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diprolene Glycol · DIN 00688622 Manufacturer: Schering Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2019-06-28 · brand DIPROLENE · ATC D07AC01 BETAMETHASONE · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Diprolene Glycol: Formulary list price $0.5186/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5186 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8190 · Verify on the e-Formulary ↗ (DIN 00688622)

Source record
DIN 00688622: Diprolene Glycol Raw flags: sec3=Y Item: 840600105; group id 838; item number 2035; lccId None; manufacturer id SCH Source form: Cr; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.5186; ministry $0.5186 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00688622 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8190 Therapeutic Notes (formulary) No more than 50 grams per week of ultrapotent steroids for a maximum of 2 weeks is recommended.
Interchangeable products
Ratio-Topilene · DIN 00849650 · $0.5186
Shortage status: discontinued (2019-07-03, reported by MERCK CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00688622
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.

CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE

Form:

5 of 5 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
  • Fluocinonide (Lyderm): general benefit, Not a benefit
  • Halobetasol (Bryhali): general benefit
  • Mometasone furoate (Elocom): general benefit

6 more in the class list below

Dovobet · DIN 02244126 · 50mcg/g & 0.5mg/g · Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dovobet · DIN 02244126 Manufacturer: Leo Pharma Inc.; listing date 2008-05-16 Health Canada: Marketed since 2001-11-29 · brand DOVOBET OINTMENT · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS, D05AX52 CALCIPOTRIOL, COMBINATIONS · form Ointment · route Topical · ingredients CALCIPOTRIOL 50 MCG/G, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G · company Leo pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.2545 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68084 · Verify on the e-Formulary ↗ (DIN 02244126)

Source record
DIN 02244126: Dovobet Raw flags: sec3=Y Item: 840600151; group id 840; item number 2043; lccId None; manufacturer id LEO Source form: Oint; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $2.1918; ministry $1.2545 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244126 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68084 Therapeutic Notes (formulary) Note: For use in patients with psoriasis who have failed 1st line topical steroids and Dovonex (calcipotriol) therapy.
Interchangeable products
Teva-Betamethasone/Calcipotriol · DIN 02427419 · $1.2545
Shortage status: resolved shortage (ended 2018-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244126
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Betamethasone/Calcipotriol · DIN 02427419 · 50mcg/g & 0.5mg/g · Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Betamethasone/Calcipotriol · DIN 02427419 Manufacturer: Teva Canada Limited; listing date 2021-04-30 Health Canada: Marketed since 2020-08-07 · brand TEVA-BETAMETHASONE/ CALCIPOTRIOL · ATC D07XC01 BETAMETHASONE, D07XC01 BETAMETHASONE · form Ointment · route Topical · ingredients CALCIPOTRIOL 50 MCG/G, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Betamethasone/Calcipotriol: Formulary list price $1.2545/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2545 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91194 · Verify on the e-Formulary ↗ (DIN 02427419)

Source record
DIN 02427419: Teva-Betamethasone/Calcipotriol Raw flags: sec3=Y Item: 840600151; group id 840; item number 2043; lccId None; manufacturer id TEV Source form: Oint; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $1.2545; ministry $1.2545 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02427419 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91194 Therapeutic Notes (formulary) Note: For use in patients with psoriasis who have failed 1st line topical steroids and Dovonex (calcipotriol) therapy.
Interchangeable products
Dovobet · DIN 02244126 · $1.2545
Shortage status: active shortage (reported 2025-12-03, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427419
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Enstilar · DIN 02457393 · 50mcg/g & 0.5mg/g · Top Aero Foam

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Enstilar · DIN 02457393 Manufacturer: Leo Pharma Inc.; listing date 2018-10-31 Health Canada: Marketed since 2016-11-11 · brand ENSTILAR · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS, D05AX52 CALCIPOTRIOL, COMBINATIONS · form Aerosol (foam) · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G, CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50 MCG/G · company Leo pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Enstilar: Formulary list price $1.6412/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6412 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94445 · Verify on the e-Formulary ↗ (DIN 02457393)

Source record
DIN 02457393: Enstilar Raw flags: sec3=Y Item: 840600154; group id 840; item number 2044; lccId None; manufacturer id LEO Source form: Top Aero Foam; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $1.6412; ministry $1.6412 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457393 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94445 Therapeutic Notes (formulary) For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457393
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dovobet Gel · DIN 02319012 · 50mcg/g & 0.5mg/g · Top Gel

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dovobet Gel · DIN 02319012 Manufacturer: Leo Pharma Inc.; listing date 2011-05-19 Health Canada: Marketed since 2012-10-12 · brand DOVOBET GEL · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS, D05AX52 CALCIPOTRIOL, COMBINATIONS · form Gel · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G, CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50 MCG/G · company Leo pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.3142 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80450 · Verify on the e-Formulary ↗ (DIN 02319012)

Source record
DIN 02319012: Dovobet Gel Raw flags: sec3=Y Item: 840600152; group id 840; item number 2045; lccId None; manufacturer id LEO Source form: Top Gel; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $2.1867; ministry $1.3142 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319012 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80450 Therapeutic Notes (formulary) Notes: For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
Interchangeable products
Taro-Calcipotriol / Betamethasone Gel · DIN 02525178 · $1.3142
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319012
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Calcipotriol / Betamethasone Gel · DIN 02525178 · 50mcg/g & 0.5mg/g · Top Gel

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Calcipotriol / Betamethasone Gel · DIN 02525178 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-06-30 Health Canada: Marketed since 2022-06-01 · brand TARO-CALCIPOTRIOL / BETAMETHASONE GEL · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS, D05AX52 CALCIPOTRIOL, COMBINATIONS · form Gel · route Topical · ingredients CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50 MCG/G, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Calcipotriol / Betamethasone Gel: Formulary list price $1.3142/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3142 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101421 · Verify on the e-Formulary ↗ (DIN 02525178)

Source record
DIN 02525178: Taro-Calcipotriol / Betamethasone Gel Raw flags: sec3=Y Item: 840600152; group id 840; item number 2045; lccId None; manufacturer id TAR Source form: Top Gel; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $1.3142; ministry $1.3142 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525178 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101421 Therapeutic Notes (formulary) Notes: For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
Interchangeable products
Dovobet Gel · DIN 02319012 · $1.3142
Shortage status: resolved shortage (ended 2026-02-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525178
Shortage record checked 2026-09-13T08:10:21.292534+00:00

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
  • Fluocinonide (Lyderm): general benefit, Not a benefit
  • Halobetasol (Bryhali): general benefit
  • Mometasone furoate (Elocom): general benefit

6 more in the class list below

Lotriderm Cream · DIN 00611174 · 1% w/w & 0.05% w/w · Top Cr

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists LOTRIDERM CREAM (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lotriderm Cream · DIN 00611174 Manufacturer: Merck Canada Inc.; listing date 2020-06-30 Health Canada: Marketed since 2022-03-10 · brand LOTRIDERM · ATC D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS, D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %, CLOTRIMAZOLE 1 % · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Lotriderm Cream: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10748 · Verify on the e-Formulary ↗ (DIN 00611174)

Source record
DIN 00611174: Lotriderm Cream Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840408056; group id 819; item number 2001; lccId None; manufacturer id MEK Source form: Top Cr; strength: 1% w/w & 0.05% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00611174 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10748
Interchangeable products
TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 · not recorded
Shortage status: resolved shortage (ended 2020-04-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00611174
Shortage record checked 2026-09-13T08:10:21.292534+00:00

TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 · 1% w/w & 0.05% w/w · Top Cr

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2020-06-30 Health Canada: Marketed since 2020-04-06 · brand TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE · ATC D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS, D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS · form Cream · route Topical · ingredients CLOTRIMAZOLE 1 %/W/W, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98629 · Verify on the e-Formulary ↗ (DIN 02496410)

Source record
DIN 02496410: TaroClotrimazole/BetamethasoneDipropiona Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840408056; group id 819; item number 2001; lccId None; manufacturer id TAR Source form: Top Cr; strength: 1% w/w & 0.05% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0832; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496410 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98629
Interchangeable products
Lotriderm Cream · DIN 00611174 · not recorded
Shortage status: resolved shortage (ended 2026-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496410
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

FLUCONAZOLE

· 8 products · Limited Use, codes 235 · strengths: 150mg · Cap

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives

Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

MOMETASONE FUROATE

· 6 products · General benefit · strengths: 0.1% · Cr, Lot, Oint

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr

HYDROCORTISONE VALERATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.2% · Cr, Oint

TRIAMCINOLONE ACETONIDE

· 5 products · Listed, not a benefit (3), General benefit (2) · strengths: 0.1% · Cr, Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 2 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DIPROSONE® (betamethasone dipropionate) is indicated for:  the topical management of corticosteroid-responsive dermatoses. Such disorder include: psoriasis, contact dermatitis (dermatitis venenata), atopic dermatitis (allergic dermatitis), neurodermatitis (lichen simplex chronicus, lichen planus, eczema, eczematous dermatitis), intertrigo, dyshidroses (pompholyx), seborrheic dermatitis, exfoliative dermatitis, solar dermatitis, stasis dermatitis, anogenital and senile pruritus. The lotion is formulated to spread easily without adherence to hairy areas to facilitate treatment of dermatoses, such as psoriasis, and seborrheic dermatitis of the scalp. 1.1 Pediatrics Pediatrics: Based on the available data, the safety and efficacy of DIPROSONE® in pediatric patients have not been established. 1.2 Geriatrics Geriatrics: There is no known evidence to suggest that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00060698.PDF PM date: April 7, 2021 Source product: DIPROSONE; DIN 00323071; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USES DIPROLENE® is indicated for the relief of the inflammatory manifestations of resistant or severe psoriasis and corticosteroid-responsive dermatoses. https://pdf.hres.ca/dpd_pm/00060715.PDF PM date: April 13, 2021 Source product: DIPROLENE; DIN 00629367; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-TOPILENE is indicated for the relief of the inflammatory manifestations of resistant or severe psoriasis and corticosteroid-responsive dermatoses. https://pdf.hres.ca/dpd_pm/00047893.PDF PM date: October 16, 2018 Source product: TEVA-TOPILENE; DIN 00849650; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications DOVOBET (calcipotriol and betamethasone dipropionate) ointment is indicated for: • the topical treatment of psoriasis vulgaris for up to 4 weeks. 1.1. Pediatrics Pediatrics (< 18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (≥ 65 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00085846.PDF PM date: 2026-08-21 Source product: DOVOBET OINTMENT; DIN 02244126; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS LOTRIDERM® Cream (betamethasone dipropionate and clotrimazole) is indicated for:  the topical treatment of the following fungal dermal infections complicated by inflammatory pruritus: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis. 1.1 Pediatrics Pediatrics: Based on the available data, the safety and effectiveness in children below the age of 12 have not been established with LOTRIDERM® Cream. 1.2 Geriatrics Geriatrics: There is insufficient data to suggest that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00060782.PDF PM date: April 20, 2021 Source product: LOTRIDERM; DIN 00611174; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Diprosone · DIN 00417246 Shortage status: discontinued (2026-06-11, reported by ORGANON CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00417246

Check this DIN again

Ratio-Topisone · DIN 00809187 Shortage status: discontinued (2024-06-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00809187

Check this DIN again

Ratio-Topisone · DIN 00805009 Shortage status: active shortage (reported 2026-06-24, estimated to end 2026-08-10, last updated 2026-06-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00805009

Check this DIN again

Ratio-Topilene · DIN 00849669 Shortage status: active shortage (reported 2024-08-28, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00849669

Check this DIN again

Diprolene Glycol · DIN 00688622 Shortage status: discontinued (2019-07-03, reported by MERCK CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00688622

Check this DIN again

Teva-Betamethasone/Calcipotriol · DIN 02427419 Shortage status: active shortage (reported 2025-12-03, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427419

Check this DIN again

Other review policies

For Lotriderm Cream, TaroClotrimazole/BetamethasoneDipropiona: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026